Revelation Biosciences, Inc.REVB

$0.98-0.09 (-8.41%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$3M

Micro-cap

-99%

2020 — today

10-Year Price

-100%

2020 — today

52-Week Range

$0.96$12.36

Current $0.98· 0%

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Valuation in context

P/E ratio

-0.1

N/A

Not meaningful — company is unprofitable

P/B ratio

0.2

Historically cheap

Historically cheap relative to the last 10 years

FCF Yield

-278.7%

Near historic low

Near historic low — last 10 years

Free · No credit card needed

Get alerted when REVB is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.